The Global Fund, PEPFAR, CIFF, and BMGF are collaborating to provide affordable access to lenacapavir for HIV prevention, aiming to reach at least 2 million people in three years. Gilead Sciences’ lenacapavir is showing promise in preventing new HIV infections and has been licensed for manufacturing in low- and lower-middle-income countries. The goal is to accelerate progress towards ending HIV/AIDS as a public health threat by 2030 through widespread access to this innovative treatment.
Full Article
Dozens of Clinical Trials Have Been Frozen in Response to Trump’s USAID Order
Asanda Zondi was ordered to remove a silicone ring preventing pregnancy and H.I.V. infection after the U.S. Agency for International Development withdrew funding for the study due to President Trump's freeze on foreign aid. Dozens of trials worldwide have been halted, leaving participants with experimental products in their bodies and researchers unable to provide care. The abrupt shutdown has violated ethical principles of medical research and destroyed trust in communities where the studies were conducted,...
Read more